文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

高度保守的β冠状病毒序列被人类T细胞广泛识别。

Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.

作者信息

Pereira Neto Tertuliano Alves, Zmasek Christian, Avalos Liliana, Sidney John, Trevizani Raphael, Phillips Elizabeth, Mallal Simon, Frazier April, Tan Gene S, Scheuermann Richard H, Sette Alessandro, Grifoni Alba

机构信息

Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.

Department of Informatics, J. Craig Venter Institute, La Jolla, CA 92037, USA.

出版信息

Cell. 2025 Jul 30. doi: 10.1016/j.cell.2025.07.015.


DOI:10.1016/j.cell.2025.07.015
PMID:40774254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12392877/
Abstract

The COVID-19 pandemic highlighted the critical need for vaccine strategies capable of addressing emerging viral threats. Betacoronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS), and SARS-CoV-2, present significant pandemic risks due to their zoonotic potential and genetic diversity. T cell-mediated immunity has demonstrated durable responses and strong cross-reactivity, offering a promising avenue for achieving broad immunity within a viral family. In this study, we combined comprehensive epitope mapping with sequence conservation analyses to identify conserved T cell epitope regions (CTERs), which constitute 12% of the complete SARS-CoV-2 proteome. We showed that SARS-CoV-2 CTER-specific T cells cross-reactively recognize sequences from multiple Betacoronavirus subgenera. Importantly, incorporating CTERs from non-spike proteins significantly enhanced T cell cross-reactivity potential and human leukocyte antigen (HLA) coverage compared with T cells targeting only spike proteins. Our findings lay the groundwork for a multi-antigen vaccine strategy that includes non-spike proteins to expand cross-reactive immunity across a broader spectrum of Betacoronaviruses.

摘要

新冠疫情凸显了对能够应对新出现病毒威胁的疫苗策略的迫切需求。包括严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS)和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在内的β冠状病毒,因其人畜共患病潜力和基因多样性而带来重大的大流行风险。T细胞介导的免疫反应已显示出持久的应答和强大的交叉反应性,为在病毒家族内实现广泛免疫提供了一条有前景的途径。在本研究中,我们将全面的表位图谱分析与序列保守性分析相结合,以识别保守的T细胞表位区域(CTERs),这些区域占完整SARS-CoV-2蛋白质组的12%。我们发现,SARS-CoV-2 CTER特异性T细胞可交叉识别多个β冠状病毒亚属的序列。重要的是,与仅靶向刺突蛋白的T细胞相比,纳入非刺突蛋白的CTERs显著增强了T细胞交叉反应性潜力和人类白细胞抗原(HLA)覆盖范围。我们的研究结果为一种多抗原疫苗策略奠定了基础,该策略包括非刺突蛋白,以在更广泛的β冠状病毒范围内扩展交叉反应性免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/2c785637997b/nihms-2098566-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/08ed44b6ddfe/nihms-2098566-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/680f2c0baf62/nihms-2098566-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/2c785637997b/nihms-2098566-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/08ed44b6ddfe/nihms-2098566-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/680f2c0baf62/nihms-2098566-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3785/12392877/2c785637997b/nihms-2098566-f0004.jpg

相似文献

[1]
Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.

Cell. 2025-7-30

[2]
A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.

Hum Vaccin Immunother. 2025-12

[3]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[4]
Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.

Front Immunol. 2025-7-17

[5]
Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.

PLoS Pathog. 2024-10

[6]
The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2.

PLoS Pathog. 2024-8

[7]
A single-dose intranasal immunization with a novel bat influenza A virus-vectored MERS vaccine provides effective protection against lethal MERS-CoV challenge.

mBio. 2025-6-30

[8]
Designing Sandwich ELISA with Broadly Reactive Anti-Nucleocapsid Monoclonal Antibodies to Detect Bat-Borne Merbecoviruses.

Viruses. 2025-6-24

[9]
Structural and functional constraints on spike activation and host protease utilization limit cell entry of SARS-CoV-2-related bat coronaviruses.

J Virol. 2025-7-24

[10]
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.

bioRxiv. 2024-10-24

本文引用的文献

[1]
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice.

Cell Host Microbe. 2024-12-11

[2]
Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants.

NPJ Vaccines. 2024-9-4

[3]
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.

Cell. 2024-10-3

[4]
Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.

Sci Transl Med. 2024-6-12

[5]
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.

Cell Rep Med. 2024-6-18

[6]
Anticipating a MERS-like coronavirus as a potential pandemic threat.

Lancet. 2024-5-4

[7]
A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies.

JCI Insight. 2024-3-8

[8]
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults.

Sci Immunol. 2024-9-2

[9]
Cross-protection induced by highly conserved human B, CD4, and CD8 T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.

Front Immunol. 2024-1-22

[10]
Overview of Nucleocapsid-Targeting Vaccines against COVID-19.

Vaccines (Basel). 2023-12-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索